非自体移植物在冠状动脉旁路移植术中的系统评价
该系统评价检索了1960年至2020年4月的文献,共纳入21项研究,评估多种非自体移植物在冠状动脉旁路移植术中的通畅率。结果显示,自体静脉内皮细胞种植的合成移植物通畅率较高(94.7%和81%),但总体而言,仍缺乏能与自体移植物媲美的替代管道。
要点
- 自体静脉内皮细胞种植的ePTFE移植物中远期通畅率可达94.7%和81%。
- 同种异体大隐静脉、牛内乳动脉等非自体移植物通畅率普遍较低。
- 非自体移植物仍无法达到自体移植物的通畅率和性能。
核心结论
- 非自体移植物中,自体静脉内皮细胞种植的合成移植物显示出有希望的结果,但需进一步研究。
研究设计与样本
- 系统评价,检索MEDLINE All、Embase Classic和Embase(通过Ovid)从1960年至2020年4月,纳入21项研究。
主要发现
- 同种异体大隐静脉109例,通畅率从中位随访8.5个月的66.7%到6-12个月和7-18个月的0%。
- ePTFE移植物29例,通畅率从中位随访5个月的80%到45个月的14.3%。
- 人脐静脉12例,中位随访6个月通畅率50%。
- Bioflow牛内乳动脉50例,平均随访9.5个月和19个月通畅率分别为15.8%和0%。
- Perma-Flow移植物39例,1-3个月和12个月通畅率分别为80%和76.9%。
关键数值与推荐
- No-React牛内乳动脉20例,中位随访28个月通畅率57.1%,平均随访7个月通畅率23.1%。
- 自体静脉内皮细胞种植的ePTFE移植物40例,平均随访27个月和60个月通畅率分别为94.7%和81%。
- 自体静脉内皮细胞种植的冷冻保存同种异体静脉12例,平均随访8.5个月通畅率83.3%。
临床怎么用
- 当缺乏合适的自体管道时,可考虑使用自体内皮细胞种植的合成移植物,但需告知患者证据有限。
局限性
- 纳入研究数量较少,各移植物样本量小,随访时间不一,通畅率定义和报告方式存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suitable autologous conduits may be lacking when performing coronary artery bypass grafting. The aim of this review is to determine the status of nonautologous grafts in coronary artery bypass grafting. METHODS: We conducted a literature search on MEDLINE All, Embase Classic, and Embase through Ovid from 1960 to April 2020. RESULTS: Of the 1579 records identified, 21 studies were included in the review. The following grafts were assessed for patency: 109 homologous saphenous veins (patency rates ranged from 66.7% at a median follow-up of 8.5 months to 0% at 6-12 months and 7-18 months, respectively), 29 expanded polytetrafluoroethylene grafts (from 80% at a median follow-up of 5 months to 14.3% at 45 months), 12 human umbilical veins (50% at a median follow-up of 6 months), 50 Bioflow bovine internal mammary arteries (from 15.8% to 0% at a mean follow-up of 9.5 months and 19 months, respectively), 39 Perma-Flow grafts (80% and 76.9% at 1-3 months and 12 months, respectively), 20 No-React bovine internal mammary arteries (57.1% at a median follow-up of 28 months and 23.1% at a mean follow-up of 7 months), 40 autologous venous endothelial cell-seeded expanded polytetrafluoroethylene grafts (94.7% and 81% at a mean follow-up of 27 months and 60 months, respectively), and 12 autologous venous endothelial cell-seeded cryopreserved homologous veins (83.3% at a mean follow-up of 8.5 months). CONCLUSIONS: The goal of an alternative conduit with patency and attributes that match those of autografts remains elusive. Autologous endothelial cell-seeded synthetic grafts have demonstrated promising results but require further investigation.
引用
- Lampridis S, George SJ. Nonautologous Grafts in Coronary Artery Bypass Surgery: A Systematic Review. Ann Thorac Surg. 2020. PMID: 33340520. doi:10.1016/j.athoracsur.2020.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。